Sunday , February 28 2021

Jon Jones granted a license of a fight to compete at UFC 235 after a long listening of the NAC

Jon Jones, in fact, will fight at UFC 235.

The heavyweight UFC heavyweight reign was licensed to compete on March 2 against Anthony Smith at the UFC 235 main event in a Tuesday session at the UFC Afternoon of the Atlantic Commission of Nevada (NAC). In a long meeting that lasted more than three hours, NAC officials determined that Jones should be tested with medications at least twice a month until the UFC 235 continues to meet a rigorous test schedule throughout the entire year 2019 if you want to fight in Nevada again.

Jones will have to pay additional drug tests in the leadership of UFC 235.

"That's on you," Commissioner Anthony Marnell told Jones. "It's on your shoulders. I like what I hear, I like what I see, but the test is in the pudding. So I'm glad you're back here, you'll always be treated with respect here, and I wanted to Make sure you get there today. Welcome back to Nevada and do it right from this point on. As you know, we will visit you frequently. "

Jones demonstrated its positive for a long-term metabolite of Turinabol oral several times during the second half of 2018. A USADA drug screening out of competition on August 9 discovered eight picograms of the long-term metabolite in Jones & # 39; system and is the first instance disclosed of this result for Jones since its failure in the 2017 drug test. A follow-up of the USADA drug test on September 18 also returned positive for 19 picograms of the same metabolite long-term. Jones was tested negatively in four consecutive drug tests: on September 21, October 2, on October 11 and November 14, before the long-term metabolite was reemerged in the rank of 60 to 80 picograms in an out of competition Trial USADA realized the 9 of December.

The December 9 drug test became the catalyst for the UFC's deployment of its December 29 show, UFC 232, from Nevada to California six days before the event. No time to review Jones's case or make an audience due to the holiday season, the Nevada Commission of the Atlantic was not prepared to grant Jones a license to compete at UFC 232.

However, due to his familiarity with Jones's case, the California State Athletic Commission (CSAC) was prepared to grant Jones's short-term license for UFC 232. As part of the terms of the CSAC to accept that Jones competed, the lightweight heavyweight champion was required to sign up for additional medication tests with the Drug Voltaire Combat Agency (VADA). Later, Jones obtained positive results for 33 picograms of the same oral metabolite of Turinabol in the long term, on December 28, in the selection of the competition conducted by VADA on the day of the pesos.

In the four positive tests, USADA and CSAC accepted that Jones was not responsible for the gross results. Instead of this, both organizations concluded that the presence of the Torinoabol oral metabolite in the long term was actually a "pulsing" remnant of the same substance that caused Jones to make a 15-month suspension in relation to the his failed drug test UFC 214 in July 2017. In this way, both organizations agreed that Jones would be allowed to compete at UFC 232, citing a logic of "double danger" similar to that preventing North American citizens, Americans were accused in criminal cases of the same crime twice.

In the afternoon hearing on Tuesday, the testimony of senior management director and research results of the USADA Jeff Cook, USADA's science director, Matthew Fedoruk, and Dr. Daniel Eichner, executive director of Salt Lake City Sports Research and Testing Laboratory, whose previous testimonials led the CSAC to allow Jones to fight against UFC 232. The three individuals responded to numerous questions about the science behind the Jones case and the handling of its results, and reiterated the point several times that current science is not able to identify an exact period of time how long the M3 metabolite can be detected in the long term of Oral Turinabol in an athlete system.

Commissioner Marnell opened a procedure calling Jones an "anomaly" that he had never seen before. He explained that the NAC's decision to allow California to move forward with Jones to UFC 232 in the short term was a decision made from conscience, not regulation, and that in any other situation in the book, "your career would end." Commissioner Chris Ault added that the case of Jones "has supported our ass in a curve."

Throughout the meeting, Marnell expressed concern that the case of Jones would not be used as a kind of free card for other fighters in the future and asked all the parties involved to work to conduct further tests Rigorous and constant to obtain more information about the long-term processes. Metabolite of the term M3 in the Jones system. At one point, Eichner observed that it was found that other substances had the same "pulsante" effect as the M3 metabolite, including clomiphene of anti-estrogen agents, which Jones proved to be ironically positive for 2016.

Notably, several NAC commissioners went against Cook for handling the case by USADA and did not publicize the multiple tests of adverse evidence of Jones in the licensing audit of December 11 CSAC in Los Angeles for UFC 232. In one of the most fierce exchanges of the day, Marnell called the USADA statements on the "weak and soft" issue.

The curators of the NAC also made a parenthesis on the ten-month window from October 2017 to August 2018, where Jones was tested for drugs zero times for USADA, despite all the that surrounds you. Cook retroactively accepted that the tests during this period could have provided useful data for the commission and USADA to weigh in the current case of Jones.

Jones finally defeated Gustfasson through third-round TKO in The Forum of Inglewood on December 29 to recover the lightweight heavyweight title at the UFC's 232 major event. He passed several tests of night fighting drugs administered by USADA and the CSAC.

Jones, 31, is a multiple offender when it comes to drug testing. "Bones" previously fulfilled a one-year suspension for a failed drug test in connection with his malicious withdrawal from UFC 200 against Daniel Cormier in July 2016. In this instance, Jones proved positive for two anti-estrogen agents in an outer – Prova de la USADA of competition. The failed test ended up striking him of a major fighting match against Cormier just a few days out of the UFC 200.

Jones (23-1, 1 NC) has never really lost to the inside of an MMA cage. The only loss of the UFC lightweight two-legged championship race was through disqualification in a controversial fight against Matt Hamill that Jones earned with pleasure. Jones's summary in the interior of the Octagon includes victories over a lot of world-class wrestlers and former champions, such as Gustafsson (x2), Ryan Bader, Mauricio Rua, Quinton Jackson, Glover Teixeira, Vitor Belfort and Rashad Evans, among others.

With the latest problems in his committee, Jones is expected to appear at a press conference in Las Vegas on Thursday, January 31, to promote his upcoming UFC 235 title defense against Anthony Smith.

Source link